Navigation Links
FASgen Announces Significant Milestone in Its Cancer Drug Development Program
Date:10/1/2007

BALTIMORE, Oct. 1 /PRNewswire/ -- FASgen's fatty acid synthase inhibitor (FASi) compounds, led by FAS031, have demonstrated efficacy against every solid tumor xenograft cell line tested, in both orthotopic and flank models: 4 lung tumor cell lines (H460; A549; H1975; LX7); two ovarian; breast; and, colon. In many cases the tumors were eradicated entirely. The compounds have been shown in extensive preclinical studies to be remarkably safe and orally available. One compound was safely given to mice twice a day orally for 6 months with no observed adverse side effects except the elimination of the tumors. Other compounds were given to mice in a two year experiment and prevented the onset of tumors in nearly one-third of the mice. That experiment was repeated with a different compound and produced the same result. Several of these results have been recently published and others will shortly be published in leading oncology journals.

FASi is a new mechanism of action for the treatment of cancer. The fatty acid biosynthesis pathway is critical to all living organisms to produce fat and regulate the body's energy. In cancer cells, FASgen researchers over the last 15 years have discovered that the mechanism acts differently. As cancer cells do not produce fat, the fatty acid biosynthesis pathway in the transformed cell acts to regulate the energy source that keeps the cell alive. One critical enzyme in that pathway is FAS. The Company's researchers have discovered that inhibition of FAS kills the cancer cell, a result that has been recently replicated in a number of labs and become the subject of a series of new publications. FASgen has developed a library of FASi compounds and has an extensive body of intellectual property surrounding both the mechanism of action and uses for the compounds, and of course the composition of individual compounds. "This discovery holds out the prospect for a new method of treatment for cancer that is remarkably safe and may diminish or even avoid many of the adverse side effects on existing chemotherapeutic drugs," said Dr. Frank Kuhajda, FASgen's chief scientific advisor and a founder of the company.

The Company is pleased with the news that NCI has agreed to support the development of these compounds at The Johns Hopkins Oncology Center through a grant to Hopkins for research into treatment of lung cancer and has been separately supporting the Company with grant funding for ovarian cancer. The Company is developing the clinical trial program to test these compounds in Phase I/II trials at Hopkins and other centers. "This news has changed the direction of the Company from a research organization to a drug development company, and, of course, has increased the need for funding. After 7 years of research, the Company is now seeking its first major round of outside financing," said Eric F. Stoer, Chairman of Board.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new a highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders, and yet an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com.


'/>"/>
SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):